1. Furukawa F. The Nobel prize in pysiology or mdicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trends in Immunotherapy 2018; 2(1). doi: 10.24294/ti.v2.i3.1065

2. Seidel JA, Otsuka A, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and lmitations. Trends in Immunotherapy 2017; 1(1): 2–9. doi: 10.24294/ti.v1.i1.20

3. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends in Immunotherapy 2020; 4(1): 18–26. doi: 10.24294/ti.v4.i1.606

4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine 2019; 381(16): 1535–1546. doi: 10.1056/NEJMoa1910836

5. Motzer RJ, Tannier NM, McDermott DF, et al. Nivolumab plus ipilimumab versus snitinib in advanced renal-cell carcinoma. New England Journal of Medicine 2018; 378: 1277–1290. doi: 10.1056/NEJMoa1712126

6. Takayasu K, Kinoshita H, Muguruma K. Durable complete response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma [in Press]. Trends in Immunotherapy 2022; 6(1) .

7. Nomizo T, Yamamoto H, Murayama T, et al. Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer [in Press]. Trends in Immunotherapy 2022; 6(1).

8. Hamatake K, Kojima K. Initiatives for immune-related adverse events by the outpatient pharmacist clinic. Trends in Immunotherapy 2022; 6(1): 3–6.